Sitagliptin 100 Mg (Generic)

Product Overview

Sitagliptin 100 Mg (Generic) is an oral antidiabetic medication indicated for the management of type 2 diabetes mellitus. Manufactured by Sun Pharmaceutical Industries Ltd, this product is supplied in packs containing 10 tablets per strip, with available pack sizes of 100, 200, or 300 tablets. The medication belongs to the dipeptidyl peptidase‑4 (DPP‑4) inhibitor class and works by enhancing the incretin hormones that stimulate insulin release and suppress glucagon secretion after meals. According to the NIH guidelines on antidiabetic agents it is intended for patients who require additional glycemic control alongside diet and exercise.

What is Sitagliptin 100 Mg (Generic)

Sitagliptin 100 Mg (Generic) contains the active pharmaceutical ingredient sitagliptin phosphate, a selective inhibitor of the enzyme DPP‑4. By preventing the rapid degradation of incretin hormones such as GLP‑1 and GIP, sitagliptin helps maintain normal blood glucose levels in adults with type 2 diabetes. The generic formulation offers the same therapeutic profile as the brand‑name version while meeting regulatory standards for strength, purity, and dosage consistency. It is presented as a film‑coated tablet delivering exactly 100 milligrams of active ingredient per dose.

Uses and Benefits

The primary use of Sitagliptin 100 Mg (Generic) is to improve glycemic control in adults diagnosed with type 2 diabetes who have not achieved adequate glucose regulation with diet and exercise alone. Clinical studies have demonstrated that the drug lowers fasting plasma glucose and reduces post‑prandial glucose spikes without causing significant hypoglycemia when used as monotherapy. Additional benefits include modest weight neutrality and a low risk of weight gain compared with some sulfonylureas. The medication is also compatible with combination therapy, allowing clinicians to add it to metformin, sulfonylureas, or insulin regimens when further control is needed.

How It Works

Sitagliptin functions by binding to the DPP‑4 enzyme located on the surface of endothelial and immune cells. This binding blocks the enzyme’s activity, leading to increased concentrations of incretin hormones that enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress hepatic glucagon release. The glucose‑dependent mechanism means that the drug’s effect is amplified only when blood glucose levels rise, which minimizes the risk of hypoglycemia. Pharmacodynamically, sitagliptin exhibits a half‑life of approximately 12 hours, supporting once‑daily dosing and steady‑state exposure after approximately one week of consistent use.

Dosage Guidelines

The recommended starting dose of Sitagliptin 100 Mg (Generic) is one tablet taken orally once daily, with or without food. For patients with moderate renal impairment (eGFR 30‑50 mL/min/1.73 m²), the dose may be reduced to 50 mg once daily to avoid accumulation. In subjects with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or those undergoing dialysis, the recommended dose is 25 mg once daily. Clinicians should adjust therapy based on therapeutic response and tolerability, but doses higher than 100 mg have not demonstrated additional benefit for glycemic control. The dosing recommendations are consistent with FDA labeling for sitagliptin.

Side Effects

Most patients tolerate Sitagliptin 100 Mg (Generic) well, but some may experience adverse effects. The most commonly reported side effects include nasopharyngitis, urinary tract infections, and headache. Less frequent but clinically relevant events comprise pancreatitis, severe joint pain, and allergic skin reactions. Rarely, cases of hypersensitivity and liver enzyme elevations have been documented. For more detailed safety information see the MedlinePlus resource. Patients should be advised to report persistent gastrointestinal symptoms, such as nausea or diarrhea, and any signs of pancreatitis, such as severe abdominal pain radiating to the back, promptly to their healthcare provider.

Warnings and Precautions

Before initiating therapy, healthcare professionals should assess renal function, as dose adjustment is essential in patients with compromised kidney function. Sitagliptin is not indicated for the treatment of type 1 diabetes or for use in patients with a history of diabetic ketoacidosis. Caution is advised in patients with a prior history of pancreatitis, as the drug may increase the risk in this subgroup. Concomitant use with strong CYP3A4 or CYP2C8 inhibitors may alter sitagliptin exposure, requiring dose modification. Additionally, the medication should be used with care in pregnant or breastfeeding women only when the expected benefit justifies potential risks, and a thorough discussion with a qualified clinician is recommended. More information is available at Drugs.com.

Frequently Asked Questions

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)